Pentixapharm Initiates Capital Expansion for PANDA Phase 3 and U.S. Growth

Pentixapharm Holding AG has announced a rights issue to finance the PANDA Phase 3 study and U.S. market expansion. The Management Board, with Supervisory Board approval, resolved a capital increase. The company plans to raise share capital from EUR 24.8 million to EUR 35.8 million with new shares, offered at a 21% discount. Major shareholder Eckert Wagniskapital will fully exercise its rights.

The focus is on the PANDA Phase 3 study of [⁶⁸Ga]Ga-PentixaFor for primary aldosteronism, critical for patient subtyping. Additional funds will support U.S. expansion and CXCR4 platform development, targeting oncology. Expected gross proceeds are EUR 20.4 million, with net proceeds of EUR 19.8 million. Subscription details will be released, with no public offering of shares in the U.S.